SLDB Solid Biosciences, Inc.

8.71-0.32 (-3.54%)
Close: August 23, 2019

9.000.29 (+3.33%)
Pre-market

Quote

Previous Close
$8.71
Day Range
$8.45-$9.34
52 Week Range
$4.32-$54.54
Volume
418,439
Avg Volume
684,386
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$400.67M
Enterprise Value (EV)
$293.96M
PE Ratio
-
EV/EBITDA
-3.97
Price/Sales
-
Price/Book
3.20
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$1.57M
EBITDA
-$74.12M
EPS, ttm
-$2.78
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/12/2019 (79 days)
Debt to Equity
1%
Debt
$15.75M
Cash
$122.46M
Net Debt
-

Performance

Beta
1.54
200 Day Moving Avg
$13.80
50 Day Moving Avg
$5.78
52 Week Change
-77.28%
YTD Change
-73.43%
1 Month Change
87.31%
3 Month Change
57.79%
6 Month Change
-11.30%
1 Year Change
-77.28%
2 Year Change
-39.00%
5 Year Change
-39.00%

Share Count

Shares Outstanding
46.0M
Float
30.3M
Restricted Shares
15.7M
Restricted Shares, %
34.12%

Solid Biosciences, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Ilan Ganot

Website: http://www.solidbio.com

Description: Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Employees: 111